Eli Lilly & Co., the biggest U.S. maker of insulin products, will pour another $700 million into manufacturing capacity, more than tripling its investment in the expanding market for diabetes treatments.
Teva Pharmaceutical Industries Ltd. Chief Executive Officer Jeremy Levin stepped down after less than 18 months on the job in a dispute with Chairman Phillip Frost over how to restructure the world’s biggest generic-drug maker.
AbbVie Inc., the drugmaker that split from Abbott Laboratories in January, reported third- quarter earnings that beat analysts’ estimates as sales of its top drug Humira increased. The company raised the bottom end of its full-year forecast.
AbbVie Inc., the drugmaker carved out of Abbott Laboratories at the start of the year, reported profit that beat analysts’ estimates and raised its 2013 forecast after sales of top medicine Humira gained on price increases and new indications.